컴피턴트 세포 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Competent Cells Market Growth & Trends:

The global competent cells market size is anticipated to reach USD 3.59 billion by 2030, exhibiting a CAGR of 8.10% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing biopharmaceutical research, advancements in gene editing technologies, and the expanding field of synthetic biology is expected to propel market growth. Moreover, the biotechnology and pharmaceutical industries depend heavily on competent cells for the production of recombinant proteins, enzymes, and vaccines. The growing need for these products in medical treatments, research, and industrial applications fuels the demand for competent cells.

The COVID-19 pandemic has significantly boosted the market for competent cells, as companies increased their research and development efforts to address immediate health and scientific challenges. Competent cells, vital for tasks like molecular cloning, genetic engineering, and making recombinant proteins, have been in higher demand due to their key role in creating vaccines, diagnostic tests, and therapeutic research. The urgent need for vaccine manufacturing and treatments for COVID-19 has driven biotech and pharmaceutical companies to improve their cloning processes. These factors have impelled the growth of the market and are anticipated to propel exponentially over the forecast period.

In addition, technological advancements in cell preparation are projected to further propel the demand for competent cells. Technological advancements in the preparation and transformation efficiency of competent cells have significantly impacted the performance and reliability of competent cells, thus increasing the demand for researchers and industrial users. Additionally, genetic modifications and stress response pathway developments have further boosted transformation accomplishment, providing tailored solutions for specific applications, and advancing the utility of competent cells in various fields. These factors are thus projected to impel the growth of the market over the forecast period.

However, the high cost of producing and maintaining high-efficiency competent cells is considerable, which may limit their accessibility, especially for smaller research institutions and startups with limited budgets. This is anticipated to affect the adoption rate of competent cells in certain markets. Moreover, the process of preparing competent cells and accomplishing successful transformations could be technically complex and involve specialized knowledge and equipment. Thereby, hampering the growth of the market over the forecast period.

Competent Cells Market Report Highlights:

• The chemically competent cells segment held the largest market share of 43.62% in 2023 due to their wide use in the field of recombinant DNA technology, and molecular biology. On the other hand, electrocompetent cells are anticipated to grow at the fastest CAGR over the forecast period.
• In 2023, the cloning segment is anticipated to dominate the market share for the application segment. However, the protein expression segment is expected to grow at the fastest CAGR of 9.04% over the forecast period driven by the increasing demand for recombinant proteins and enzymes required in various industrial and academic applications.
• The pharmaceutical & biotechnology companies segment dominated the end-use segment with the largest share in 2023 due to the rising demand for competent cells for drug discovery and development, along with the few qualitative tests required to fulfill the regulatory standards.
• The North America region dominated the market with a share of 34.13% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Competent Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing demand for recombinant proteins and antibodies
    • 3.2.1.2. Growing biotechnology and pharmaceutical industries
    • 3.2.1.3. Increasing research and development activities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs of Competent Cells
• 3.3. Competent Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Competent Cells Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Competent Cells Market Type Movement Analysis
• 4.3. Global Competent Cells Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Chemically Competent Cells
  • 4.4.1. Chemically competent cells market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Electrocompetent Cells
  • 4.5.1. Electrocompetent cells market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Ultracompetent Cells
  • 4.6.1. Ultracompetent cells market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competent Cells Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Competent Cells Market Application Movement Analysis
• 5.3. Global Competent Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Cloning
  • 5.4.1. Cloning market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Protein Expression
  • 5.5.1. Protein expression market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Mutagenesis
  • 5.6.1. Mutagenesis market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competent Cells Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Competent Cells Market End-use Movement Analysis
• 6.3. Global Competent Cells Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competent Cells Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Regulatory framework
    • 7.5.9.3. Competitive scenario
    • 7.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Regulatory framework
    • 7.8.5.3. Competitive scenario
    • 7.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Agilent Technologies, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Takara Bio Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. New England Biolabs (UK) Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Promega Corporation
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Bio-Rad Laboratories
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Roche Applied Science
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Qiagen
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. SGI-DNA (Synthetic Genomics, Inc.)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives